Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

2.55 

0.05 2.0%

as of Mar 21 '23

52 Week Range:

2.37 69.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 2.79
3.14
3.37
3.94
4.21
4.11
3.93
4.56
4.90
5.11
6.28
growth rate 12.5% 7.3% 16.9% 6.9% -2.4% -4.4% 16.0% 7.5% 4.3% 22.9%
Earnings BIT 155.90
182.60
207.80
235.60
275.20
304.40
266.10
426.10
growth rate 17.1% 13.8% 13.4% 16.8% 10.6% -12.6% 60.1%
Avg.PE 24.07
23.79
48.14
29.21
24.60
31.50
31.50
growth rate -1.2% 102.4% -39.3% -15.8% 28.1% 0.0%
ROA 5.66
4.35
4.17
2.94
5.65
8.68
4.18
8.82
8.05
5.42
8.27
growth rate -23.1% -4.1% -29.5% 92.2% 53.6% -51.8% 111.0% -8.7% -32.7% 52.6%
ROE 16.11
11.67
10.32
7.03
13.62
21.75
11.13
22.16
21.87
16.90
27.28
growth rate -27.6% -11.6% -31.9% 93.7% 59.7% -48.8% 99.1% -1.3% -22.7% 61.4%
ROIC 11.01
8.76
7.86
5.58
10.53
15.77
7.87
15.70
13.72
9.06
13.21
growth rate -20.4% -10.3% -29.0% 88.7% 49.8% -50.1% 99.5% -12.6% -34.0% 45.8%
Cur. Ratio 1.58
1.92
2.21
2.34
2.22
2.43
2.59
2.18
2.78
2.43
2.63
growth rate 21.5% 15.1% 5.9% -5.1% 9.5% 6.6% -15.8% 27.5% -12.6% 8.2%
Quick Ratio 0.70
0.88
1.15
1.35
1.27
1.42
1.45
1.13
1.62
1.35
1.69
growth rate 25.7% 30.7% 17.4% -5.9% 11.8% 2.1% -22.1% 43.4% -16.7% 25.2%
Leverage 2.75
2.63
2.35
2.43
2.38
2.63
2.69
2.37
3.06
3.17
3.41
growth rate -4.4% -10.7% 3.4% -2.1% 10.5% 2.3% -11.9% 29.1% 3.6% 7.6%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 293.20
234.70
243.90
319.30
383.10
406.10
377.10
463.00
growth rate -20.0% 3.9% 30.9% 20.0% 6.0% -7.1% 22.8%
Acct.Payable 76.00
72.10
86.10
90.80
104.50
118.40
134.60
147.40
growth rate -5.1% 19.4% 5.5% 15.1% 13.3% 13.7% 9.5%
Cur.Assets 1,366.30
1,231.50
1,275.90
1,358.80
1,304.30
1,796.30
1,925.00
2,471.80
growth rate -9.9% 3.6% 6.5% -4.0% 37.7% 7.2% 28.4%
Total Assets 1,864.80
1,730.00
1,808.40
1,948.50
2,128.60
2,771.50
3,049.00
3,650.00
growth rate -7.2% 4.5% 7.8% 9.2% 30.2% 10.0% 19.7%
Cash 319.50
267.10
342.40
325.00
322.40
678.30
681.80
1,068.20
growth rate -16.4% 28.2% -5.1% -0.8% 110.4% 0.5% 56.7%
Inventory 477.40
422.00
440.40
486.20
509.60
577.20
692.30
710.10
growth rate -11.6% 4.4% 10.4% 4.8% 13.3% 19.9% 2.6%
Cur.Liabilities 582.70
554.50
524.70
524.50
599.30
645.60
791.90
938.50
growth rate -4.8% -5.4% 0.0% 14.3% 7.7% 22.7% 18.5%
Liabilities 1,093.10
997.10
1,115.30
1,215.00
1,200.90
1,833.30
2,074.70
2,565.20
growth rate -8.8% 11.9% 8.9% -1.2% 52.7% 13.2% 23.6%
LT Debt 354.20
265.20
391.60
414.30
315.50
828.60
896.90
1,237.30
growth rate -25.1% 47.7% 5.8% -23.9% 162.6% 8.2% 38.0%
Equity 765.90
726.10
686.40
725.40
896.60
906.80
961.20
1,070.50
growth rate -5.2% -5.5% 5.7% 23.6% 1.1% 6.0% 11.4%
Common Shares 167.00
167.00
169.00
170.00
169.00
162.00
159.00
1.70
1.70
1.70
1.70
growth rate 0.0% 1.2% 0.6% -0.6% -4.1% -1.9% -98.9% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 33.80
34.20
37.10
43.70
49.20
73.00
97.20
92.00
growth rate 1.2% 8.5% 17.8% 12.6% 48.4% 33.2% -5.4%
Cash Dividends 25.80
25.80
25.80
25.40
25.10
25.00
24.60
24.20
growth rate 0.0% 0.0% -1.6% -1.2% -0.4% -1.6% -1.6%
Cash From OA 114.30
229.20
130.80
154.40
239.70
213.40
332.20
282.40
growth rate 100.5% -42.9% 18.0% 55.3% -11.0% 55.7% -15.0%
FCF per Share 0.18
0.33
0.17
0.68
0.64
0.88
0.52
0.95
0.82
0.89
1.46
growth rate 83.3% -48.5% 300.0% -5.9% 37.5% -40.9% 82.7% -13.7% 8.5% 64.0%
Sale Purchase of Stock 8.20
10.80
11.50
20.00
growth rate 31.7% 6.5% 73.9%
FCF 33.00
60.00
95.00
81.00
195.00
94.00
111.00
191.00
140.00
235.00
190.00
growth rate 81.8% 58.3% -14.7% 140.7% -51.8% 18.1% 72.1% -26.7% 67.9% -19.2%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 1,808.90
1,623.80
1,611.30
1,765.90
1,895.60
2,072.60
1,987.50
2,417.90
growth rate -10.2% -0.8% 9.6% 7.3% 9.3% -4.1% 21.7%
Op.Income 155.90
182.60
207.80
235.60
275.20
304.40
266.10
426.10
growth rate 17.1% 13.8% 13.4% 16.8% 10.6% -12.6% 60.1%
IBT 101.30
128.00
177.60
197.80
244.70
280.40
225.80
393.60
growth rate 26.4% 38.8% 11.4% 23.7% 14.6% -19.5% 74.3%
Net Income 56.70
101.60
153.60
78.60
179.70
197.20
157.80
277.10
growth rate 79.2% 51.2% -48.8% 128.6% 9.7% -20.0% 75.6%
EPS 0.55
0.46
0.48
0.33
0.60
0.95
0.49
1.14
1.26
1.02
1.81
growth rate -16.4% 4.4% -31.3% 81.8% 58.3% -48.4% 132.7% 10.5% -19.1% 77.5%
Gross Profit 788.30
729.80
756.30
821.60
906.50
1,000.60
944.40
1,213.70
growth rate -7.4% 3.6% 8.6% 10.3% 10.4% -5.6% 28.5%
R&D 174.20
145.70
147.90
161.60
173.40
187.70
198.00
220.80
growth rate -16.4% 1.5% 9.3% 7.3% 8.3% 5.5% 11.5%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 89.60
114.40
129.80
102.40
86.00
growth rate 27.7% 13.5% -21.1% -16.0%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 390.40
428.50
463.00
460.20
457.80
growth rate 9.8% 8.1% -0.6% -0.5%
Acct.Payable 142.60
141.10
147.40
161.20
154.90
growth rate -1.1% 4.5% 9.4% -3.9%
Cur.Assets 1,968.20
1,989.30
2,471.80
2,250.80
2,087.50
growth rate 1.1% 24.3% -8.9% -7.3%
Total Assets 3,087.00
3,127.70
3,650.00
3,550.70
3,384.80
growth rate 1.3% 16.7% -2.7% -4.7%
Cash 608.10
573.00
1,068.20
816.10
723.00
growth rate -5.8% 86.4% -23.6% -11.4%
Inventory 730.20
732.80
710.10
739.90
759.00
growth rate 0.4% -3.1% 4.2% 2.6%
Cur.Liabilities 954.60
921.20
938.50
880.50
818.40
growth rate -3.5% 1.9% -6.2% -7.1%
Liabilities 2,071.30
2,037.80
2,565.20
2,512.60
2,394.10
growth rate -1.6% 25.9% -2.1% -4.7%
LT Debt 743.90
732.00
1,237.30
1,217.00
1,174.30
growth rate -1.6% 69.0% -1.6% -3.5%
Equity 1,002.00
1,075.60
1,070.50
1,017.00
970.50
growth rate 7.4% -0.5% -5.0% -4.6%
Common Shares 1.70
1.70
1.70
1.70
1.70
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 22.60
16.30
28.40
19.00
17.90
growth rate -27.9% 74.2% -33.1% -5.8%
Cash Dividends 6.00
6.10
6.00
7.50
7.50
growth rate 1.7% -1.6% 25.0% 0.0%
Cash From OA 21.90
23.90
138.60
77.80
-44.40
growth rate 9.1% 479.9% -43.9% -100.0%
Sale Purchase of Stock
growth rate
FCF -0.70
7.60
110.20
58.80
-62.30
growth rate 100.0% 1,350.0% -46.6% -100.0%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 570.80
608.90
683.50
595.00
588.40
growth rate 6.7% 12.3% -13.0% -1.1%
Op.Income 89.60
114.40
129.80
102.40
86.00
growth rate 27.7% 13.5% -21.1% -16.0%
IBT 80.00
108.80
119.50
94.00
69.60
growth rate 36.0% 9.8% -21.3% -26.0%
Net Income 57.60
87.10
75.70
61.60
49.50
growth rate 51.2% -13.1% -18.6% -19.6%
Gross Profit 280.90
309.00
344.10
306.40
299.50
growth rate 10.0% 11.4% -11.0% -2.3%
R&D 55.80
52.10
58.10
56.60
59.60
growth rate -6.6% 11.5% -2.6% 5.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (72.06)

YOY Growth Grade:

D (35.20)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 74.29 3.01 28.25
EPS / Growth 16.4% 0.85 18.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 8.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 8.2% 14.2% 14.2%
Future PE 16.34 28.33 28.33
Future EPS 1.86 3.20 3.20
Value Price
MOS %
7.51
194.6%
22.40
778.4%
22.40
778.4%
MOS Price 3.76 11.20 11.20
IRT 2.60 2.38 2.38

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.